BridgeMD
Waiting on Atrial fibrillation Intervention Therapy (WAIT) Study
EU CTIS ID: 2025-524182-25-00
What this study is testing
The primary objective of this trial is to evaluate whether treatment with a GLP-1 receptor agonist (semaglutide) in overweight or obese patients scheduled for first-time catheter ablation for atrial fibrillation can improve arrhythmia-free survival at 12 months post-ablation compared to standard of care.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Provision of written informed consent prior to participation.
- Age ≥18 years
- Scheduled for first-time catheter ablation for atrial fibrillation using a pulmonary vein isolation (PVI) technique.
- 4. Body Mass Index (BMI) ≥30 kg/m² (obesity) OR BMI ≥27 kg/m² (overweight) with one or more of the comorbidities listed in the protocol under section 6.1, inclusion criteria nr. 4.
- 5. For women of childbearing potential: Inclusion after a highly sensitive negative pregnancy test and agreement to use highly effective contraception during the study period (e.g., hormonal contraception, intrauterine device, or barrier method combined with spermicide).
You likely can't join if
- Morbid obesity (BMI >40 kg/m²).
- History of pancreatitis or recurrent hypoglycemia.
- Uncontrolled diabetic retinopathy
- Severe renal failure (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m² or in dialysis)
- Severe hepatic failure (decompensated liver disease Child–Pugh class C)
- Severe cardiac failure (NYHA class IV)
See the full eligibility criteria
- Provision of written informed consent prior to participation.
- Age ≥18 years
- Scheduled for first-time catheter ablation for atrial fibrillation using a pulmonary vein isolation (PVI) technique.
- 4. Body Mass Index (BMI) ≥30 kg/m² (obesity) OR BMI ≥27 kg/m² (overweight) with one or more of the comorbidities listed in the protocol under section 6.1, inclusion criteria nr. 4.
- 5. For women of childbearing potential: Inclusion after a highly sensitive negative pregnancy test and agreement to use highly effective contraception during the study period (e.g., hormonal contraception, intrauterine device, or barrier method combined with spermicide).
- Morbid obesity (BMI >40 kg/m²).
- History of pancreatitis or recurrent hypoglycemia.
- Uncontrolled diabetic retinopathy
- Severe renal failure (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m² or in dialysis)
- Severe hepatic failure (decompensated liver disease Child–Pugh class C)
- Severe cardiac failure (NYHA class IV)
- Diabetes type 1
- Life expectancy <12 months.
- Inability to self-administer the investigational medicinal product.
- Prior catheter ablation procedure for atrial fibrillation.
- Pregnancy, breastfeeding, or planned pregnancy during or within two months after the study period.
- Participation in another interventional clinical trial within the past 30 days.
- Current use of GLP-1 receptor agonist therapy or dual agonist therapy within 6 months before screening.
- Current use of DPP-IV inhibitors
- Known intolerance or contraindication to semaglutide.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.